U.S. vaccine approval postponed after AstraZeneca’s hottest… Early April vaccination

The estimated time of approval for the Corona 19 vaccine developed by Oxford University in the UK and the pharmaceutical company AstraZeneca, which the US government has decided to introduce in Korea, has been slightly delayed to April this year. This is because the effect is not clear.

According to the Wall Street Journal (WSJ) on the 30th (local time), Montseff Slawi, chief executive of the Donald Trump administration’s Corona 19 vaccine development program,’Ultra-fast Operation’, said, “If everything goes well, the emergency use of the AstraZeneca vaccine is probably It is expected to be approved in April of next year.” This is a delay of at least two months from February this year, when the White House expected approval.

The WSJ reported that the U.S. quarantine authorities delayed the expected timing of urgent approval of the AstraZeneca vaccine due to questions surrounding its effectiveness. The vaccine of AstraZeneca reaches 90% of the preventive effect if half of the dose is first inoculated and one additional dose is completely added a month later. Participants in some trials were given only half of the first dose due to the researchers’ mistake. However, as with other vaccines, when the entire dose was normally administered twice, the preventive effect fell to 62%. The average prevention rate is 70.4%, which is lower than that of Pfizer (95.0%) and Modena (94.5%).

“There is a need for specific and clear numbers, and little is known about the effectiveness of the AstraZeneca vaccine against the elderly,” said Slawi. The US government has ordered 300 million doses of AstraZeneca vaccine.

Following the British government, Argentina and El Salvador in Latin America approved the emergency use of the AstraZeneca vaccine. Approval from the Indian quarantine authorities is also imminent.

The Chinese government conditionally approved the Corona 19 vaccine developed by its domestic pharmaceutical company Sinoparm. According to the Shinhwa news agency, the State Council said, “The prevention rate of the synopam vaccine is 79.34%.”

Reporter Kim Jung-eun/Beijing = Correspondent Kang Hyun-woo [email protected]

Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution

Source